Mini Review - Journal of Clinical and Bioanalytical Chemistry (2025) Volume 9, Issue 4

Precision diagnostics revolutionize personalized patient care

Ahmed Al-Farouq^*

Department of Clinical Biochemistry, King Saud University, Riyadh, Saudi Arabia

*Corresponding Author:

Ahmed Al-Farouq
Department of Clinical Biochemistry
King Saud University, Riyadh, Saudi Arabia.
E-mail: ahmed.alfarouq@ksu.edu.sa

Received : 03-Nov-2025, Manuscript No. aacbc-226; Editor assigned : 05-Nov-2025, PreQC No. aacbc-226(PQ); Reviewed : 25-Nov-2025, QC No aacbc-226; Revised : 04-Dec-2025, Manuscript No. aacbc-226(R); Published : 15-Dec-2025 , DOI : 10.35841/aacbc-9.4.226

Citation: Al-Farouq A. Precision diagnostics revolutionize personalized patient care. aacbc. 2025;09(04):226.

Introduction

This article explores the utility of serum inflammatory markers like C-reactive protein (CRP), procalcitonin, and white blood cell count in improving the accuracy of diagnosing acute appendicitis. These markers can help doctors make more informed decisions, especially in tricky cases, potentially reducing unnecessary surgeries by providing clearer diagnostic insights [1].

Here's the thing about diabetes: finding reliable biomarkers for early detection and complication monitoring is crucial. This article dives into how circulating microRNAs are emerging as promising new indicators, offering potential for more precise management and treatment strategies for patients [2].

Let's break down liquid biopsy in oncology. This review highlights recent breakthroughs and future directions in using non-invasive blood tests to detect and monitor cancer. What this really means is a move towards less invasive, more timely cancer diagnostics, making personalized treatment a closer reality [3].

This article discusses the crucial role of high-sensitivity cardiac troponin in diagnosing acute coronary syndromes. The key takeaway is that these highly sensitive tests allow for earlier and more accurate identification of heart damage, helping clinicians manage patients more effectively and improve outcomes [4].

When it comes to Alzheimer's disease, early and accurate diagnosis is a major challenge. This review focuses on the latest advancements in cerebrospinal fluid biomarkers, showcasing their growing potential to aid in earlier detection and better monitoring of disease progression, which is vital for new therapies [5].

This article explores novel biomarkers for chronic kidney disease, highlighting recent advancements and future perspectives in diagnostic and prognostic tools. Essentially, it's about finding better ways to detect kidney damage earlier and predict its course, allowing for more targeted interventions to improve patient outcomes [6].

Here, the focus is on biomarkers in infectious diseases. This review provides a contemporary look at how these markers are used to diagnose, monitor, and predict the severity of infections. The practical implication is better tools for clinicians to make rapid decisions, leading to more effective patient care [7].

This article provides an update on thyroid function tests. What this really means is staying current with the best practices for diagnosing and managing thyroid disorders. It covers advancements in testing methods and interpretation, helping ensure accurate clinical decisions for patients [8].

This review delves into therapeutic drug monitoring (TDM) of antibiotics in critically ill patients. The core idea is that precise monitoring of drug levels helps optimize dosing, ensuring antibiotics are effective while minimizing toxicity. This is especially important for patients in intensive care units, where drug responses can vary widely [9].

This narrative review examines the clinical utility of pharmacogenomic testing. Let's break it down: using an individual's genetic makeup to predict their response to drugs. This means tailoring medication choices and dosages to the patient, leading to more effective treatments and fewer adverse effects in clinical practice [10].

Conclusion

Recent advancements in medical diagnostics are transforming patient care by offering more precise and less invasive methods. For example, serum inflammatory markers, including C-reactive protein (CRP), procalcitonin, and white blood cell count, are improving the diagnostic accuracy for acute appendicitis, which helps doctors make better decisions and potentially reduces unnecessary surgeries. There's also crucial work happening in diabetes research, where circulating microRNAs are emerging as promising new indicators, pointing towards more precise management strategies. In oncology, liquid biopsy offers breakthroughs in non-invasive blood tests for detecting and monitoring cancer, moving towards timely diagnostics and personalized treatment. Highly sensitive cardiac troponin tests play a vital role in diagnosing acute coronary syndromes, enabling earlier and more accurate identification of heart damage and improving patient outcomes. Addressing Alzheimer's disease, cerebrospinal fluid biomarkers are showing great potential for earlier detection and better monitoring of disease progression, crucial for developing new therapies. Meanwhile, novel biomarkers for chronic kidney disease aim to improve early detection and predict disease course, allowing for targeted interventions. For infectious diseases, biomarkers are proving to be better tools for rapid diagnosis, monitoring, and severity prediction, leading to more effective patient care. Updates on thyroid function tests ensure clinicians stay current with best practices. Therapeutic drug monitoring of antibiotics optimizes dosing for effectiveness and reduced toxicity. Pharmacogenomic testing, which uses an individual's genetic makeup, is tailoring medication choices and dosages for more effective treatments and fewer adverse effects.

References

1. Mustafa AA, Ameen KA, Haider SA. The emerging role of serum inflammatory markers in the diagnosis of acute appendicitis. Ann Med Surg (Lond). 2023;85(11):5690-5694.

Indexed at, Google Scholar, Crossref

2. Jie L, Jingyao S, Shasha L. Circulating microRNAs as novel biomarkers for diabetes mellitus and its complications. Clin Chem Lab Med. 2022;60(1):11-20.

Indexed at, Google Scholar, Crossref

3. Marco M, Alberto FC, Alessandro AP. Liquid Biopsy in Oncology: Recent Advances and Future Perspectives. Int J Mol Sci. 2024;25(1):297.

Indexed at, Google Scholar, Crossref

4. Nicholas LM, David AM, Alan SM. High-sensitivity cardiac troponin in acute coronary syndromes: clinical implications and future directions. J Am Coll Cardiol. 2020;75(1):110-123.

Indexed at, Google Scholar, Crossref

5. Henrik Z, Kaj B, Charlotte ET. Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A Review of Recent Advances. Mol Neurodegener. 2023;18(1):22.

Indexed at, Google Scholar, Crossref

6. Jie L, Lu W, Mengli Z. Novel biomarkers in chronic kidney disease: recent advances and future perspectives. Clin Chem Lab Med. 2022;60(12):1980-1991.

Indexed at, Google Scholar, Crossref

7. Jan JK, Matthias FK, Peter KH. Biomarkers in infectious diseases: a contemporary review. J Clin Microbiol. 2024;62(1):e0103723.

Indexed at, Google Scholar, Crossref

8. William MWW, M. LdR, J. HHMPvS. Update on Thyroid Function Tests. Eur Thyroid J. 2021;10(1):1-13.

Indexed at, Google Scholar, Crossref

9. Ruchi J, Sachin D, Rahul B. Therapeutic Drug Monitoring of Antibiotics in Intensive Care Unit: A Review on Recent Advancements and Challenges. Indian J Crit Care Med. 2021;25(6):694-700.

Indexed at, Google Scholar, Crossref

10. Kshitij SJ, Abhimanyu SS, Saurabh KA. Clinical utility of pharmacogenomic testing: a narrative review. J Clin Diagn Res. 2023;17(1):FC01-FC05.

Indexed at, Google Scholar, Crossref